5rdm: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==PanDDA analysis group deposition -- Endothiapepsin ground state model 46== | ==PanDDA analysis group deposition -- Endothiapepsin ground state model 46== | ||
<StructureSection load='5rdm' size='340' side='right'caption='[[5rdm]]' scene=''> | <StructureSection load='5rdm' size='340' side='right'caption='[[5rdm]], [[Resolution|resolution]] 1.01Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5RDM OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5RDM FirstGlance]. <br> | <table><tr><td colspan='2'>[[5rdm]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Cryphonectria_parasitica Cryphonectria parasitica]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5RDM OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5RDM FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5rdm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5rdm OCA], [http://pdbe.org/5rdm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5rdm RCSB], [http://www.ebi.ac.uk/pdbsum/5rdm PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5rdm ProSAT]</span></td></tr> | </td></tr><tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Endothiapepsin Endothiapepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.22 3.4.23.22] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5rdm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5rdm OCA], [http://pdbe.org/5rdm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5rdm RCSB], [http://www.ebi.ac.uk/pdbsum/5rdm PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5rdm ProSAT]</span></td></tr> | |||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Crystallographic fragment screening (CFS) provides excellent starting points for projects concerned with drug discovery or biochemical tool compound development. One of the fundamental prerequisites for effective CFS is the availability of a versatile fragment library. Here, we report on the assembly of the 1,103-compound F2X-Universal Library and its 96-compound sub-selection, the F2X-Entry Screen. Both represent the available fragment chemistry and are highly diverse in terms of their 3D-pharmacophore variations. Validation of the F2X-Entry Screen in CFS campaigns using endothiapepsin and the Aar2/RNaseH complex yielded hit rates of 30% and 21%, respectively, and revealed versatile binding sites. Dry presentation of the libraries allows CFS campaigns to be carried out with or without the co-solvent DMSO present. Most of the hits in our validation campaigns could be reproduced also in the absence of DMSO. Consequently, CFS can be carried out more efficiently and for a wider range of conditions and targets. | |||
F2X-Universal and F2X-Entry: Structurally Diverse Compound Libraries for Crystallographic Fragment Screening.,Wollenhaupt J, Metz A, Barthel T, Lima GMA, Heine A, Mueller U, Klebe G, Weiss MS Structure. 2020 Jun 2;28(6):694-706.e5. doi: 10.1016/j.str.2020.04.019. Epub 2020, May 14. PMID:32413289<ref>PMID:32413289</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 5rdm" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Cryphonectria parasitica]] | |||
[[Category: Endothiapepsin]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: | [[Category: Barthel, T]] | ||
[[Category: Heine, A]] | |||
[[Category: Klebe, G]] | |||
[[Category: Lima, G M.A]] | |||
[[Category: Metz, A]] | |||
[[Category: Mueller, U]] | |||
[[Category: Weiss, M S]] | |||
[[Category: Wollenhaupt, J]] | |||
[[Category: F2x-entry]] | |||
[[Category: Fragmax]] | |||
[[Category: Fragmaxapp]] | |||
[[Category: Fragment screening]] | |||
[[Category: Hydrolase]] | |||
[[Category: Inhibition]] | |||
Revision as of 13:28, 17 June 2020
PanDDA analysis group deposition -- Endothiapepsin ground state model 46PanDDA analysis group deposition -- Endothiapepsin ground state model 46
Structural highlights
Publication Abstract from PubMedCrystallographic fragment screening (CFS) provides excellent starting points for projects concerned with drug discovery or biochemical tool compound development. One of the fundamental prerequisites for effective CFS is the availability of a versatile fragment library. Here, we report on the assembly of the 1,103-compound F2X-Universal Library and its 96-compound sub-selection, the F2X-Entry Screen. Both represent the available fragment chemistry and are highly diverse in terms of their 3D-pharmacophore variations. Validation of the F2X-Entry Screen in CFS campaigns using endothiapepsin and the Aar2/RNaseH complex yielded hit rates of 30% and 21%, respectively, and revealed versatile binding sites. Dry presentation of the libraries allows CFS campaigns to be carried out with or without the co-solvent DMSO present. Most of the hits in our validation campaigns could be reproduced also in the absence of DMSO. Consequently, CFS can be carried out more efficiently and for a wider range of conditions and targets. F2X-Universal and F2X-Entry: Structurally Diverse Compound Libraries for Crystallographic Fragment Screening.,Wollenhaupt J, Metz A, Barthel T, Lima GMA, Heine A, Mueller U, Klebe G, Weiss MS Structure. 2020 Jun 2;28(6):694-706.e5. doi: 10.1016/j.str.2020.04.019. Epub 2020, May 14. PMID:32413289[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||